Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

FDA decision by end of January?

$Zevra Therapeutics (ZVRA.US)$  The NDA filed on Dec. 22 is expected to be classified as a Class II submission, which will be subject to a six-month review. The FDA's decision to accept the NDA is expected within 30 days. Make a note to keep watch!
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
Translate
Report
4428 Views
Comment
Sign in to post a comment